• Azenta reported Q3 fiscal 2026 revenue of $161 million, up 12% year over year; adjusted EPS was $0.16.
• Adjusted EBITDA margin fell 0.6 percentage points to 11.4%; free cash flow was negative $5 million.
• Results reflected strength in recurring revenue businesses including Biorepositories and C&I, while Sanger sequencing continued to decline year over year.
• Cash and marketable securities totaled $529 million as of June 30, 2026; no debt outstanding.
• For Q4 fiscal 2026, organic revenue is expected to decline low single-digit; adjusted EBITDA is guided to $20 million-$23 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azenta Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.